A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Amgen 509 20180146 Prostate Cancer Study

Description

This study is being done to learn more about the drug; AMG 509 (xaluritamig) when used alone or in combination with either abiraterone or enzalutamide in men the metastatic prostate cancer. Participants will be in the study for 3 yrs. The study plans to enroll approximately 470 participants.
Protocol#: AMGEN-509-20180146

Study Information

Age Group: Adults
Participating Sites: Sanford Sioux Falls Region
Scope:
Phase: I

Principal Investigator(s)

Christopher Sumey

Department

Management Group: Genitourinary - Oncology
NCT: NCT04221542

Contact Us

For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Sioux Falls Region: (605) 328-1368